Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has earned a consensus recommendation of “Buy” from the thirteen brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $20.65.
INO has been the topic of several research reports. Nomura reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Inovio Pharmaceuticals in a research report on Monday, May 1st. Jefferies Group LLC reaffirmed a “neutral” rating and issued a $38.00 price objective on shares of Inovio Pharmaceuticals in a research report on Monday, May 1st. Zacks Investment Research cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, April 17th. ValuEngine raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Finally, Maxim Group reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Inovio Pharmaceuticals in a research report on Thursday, June 1st.
In other Inovio Pharmaceuticals news, Director David B. Weiner sold 8,000 shares of the business’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $8.00, for a total transaction of $64,000.00. Following the sale, the director now directly owns 740,956 shares of the company’s stock, valued at approximately $5,927,648. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Morton Collins purchased 21,300 shares of the business’s stock in a transaction on Monday, March 27th. The shares were acquired at an average cost of $6.25 per share, for a total transaction of $133,125.00. Following the completion of the transaction, the director now directly owns 142,291 shares in the company, valued at $889,318.75. The disclosure for this purchase can be found here. Insiders own 10.60% of the company’s stock.
A number of large investors have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new stake in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $559,000. Keybank National Association OH boosted its stake in shares of Inovio Pharmaceuticals by 6.9% in the fourth quarter. Keybank National Association OH now owns 30,242 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 1,950 shares during the last quarter. ARK Investment Management LLC purchased a new stake in shares of Inovio Pharmaceuticals during the fourth quarter worth about $217,000. Thomas J. Herzfeld Advisors Inc. purchased a new stake in shares of Inovio Pharmaceuticals during the fourth quarter worth about $104,000. Finally, Vident Investment Advisory LLC boosted its stake in shares of Inovio Pharmaceuticals by 67.5% in the fourth quarter. Vident Investment Advisory LLC now owns 106,147 shares of the biopharmaceutical company’s stock worth $737,000 after buying an additional 42,764 shares during the last quarter. 27.73% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Inovio Pharmaceuticals, Inc. (INO) Receives $20.65 Consensus Target Price from Analysts” was originally posted by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.wkrb13.com/markets/2229199/inovio-pharmaceuticals-inc-ino-receives-20-65-consensus-target-price-from-analysts.html.
Inovio Pharmaceuticals (NASDAQ INO) traded up 1.03% during mid-day trading on Tuesday, hitting $7.84. The stock had a trading volume of 2,074,111 shares. The company has a 50-day moving average price of $7.30 and a 200 day moving average price of $6.82. Inovio Pharmaceuticals has a 1-year low of $5.83 and a 1-year high of $11.61. The company’s market cap is $585.08 million.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.31). Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The company had revenue of $10.40 million during the quarter, compared to analyst estimates of $5.83 million. During the same quarter in the previous year, the business earned ($0.11) EPS. The firm’s revenue was up 28.4% on a year-over-year basis. Equities research analysts forecast that Inovio Pharmaceuticals will post ($1.10) EPS for the current fiscal year.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229199/inovio-pharmaceuticals-inc-ino-receives-20-65-consensus-target-price-from-analysts.html
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.